You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆指跌幅擴至逾300點失萬五關 潤地挫逾9% 港交所及恆生跌4%
恆指繼上周續累挫近5.8%,今早反彈54點至15,362無以為繼,掉頭倒跌334點或2.2%,報14,974點,再創逾14個月低,總成交額476億元。此外,科指下滑2.8%報3,042點再創逾14個月低。 藍籌近乎全面下跌,內房股沽壓較大,尤其是潤地(01109.HK)續挫逾9%報20.9元創逾六年半低;龍湖(00960.HK)續挫近6%報8.33元;中海外(00688.HK)跌3.5%曾低見10.94元創新低。 百威亞太(01876.HK)續挫逾8%報11.1元創上市新低。蒙牛(02319.HK)、李寧(02331.HK)及潤啤(00291.HK)續跌逾4%-5%齊尋底。美團(03690.HK)挫6%報64.5元,創近四年半低;海底撈(06862.HK)續挫6.6%報12.22元再創約14個月低。 醫藥股及醫療平台服務股全線跌逾2%-5.5%,藥明生物(02269.HK)、國藥(01099.HK)、京東健康(06618.HK)及翰森(03692.HK)沽壓最大。 金融股以港交所(00388.HK)沽壓最大,股價挫3.8%報220.8元,創逾一年低。恆生(00011.HK)續跌4%曾低見78.95元創新低。此外,騰訊(00700.HK)及百度(09888.HK)續挫3%及3.5%。(sz/w) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account